{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342378","form_type":"8-K","ticker":"ALMR","cik":"0002104204","company_name":"Alamar Biosciences, Inc.","filed_at":"2026-08-10T20:10:17+00:00","discovered_at":"2026-08-10T20:11:00.355851+00:00","generated_at":"2026-08-10T20:11:28.167574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M","bullets":["Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.","Gross margin improved to 60% vs 53% YoY; operating loss widened to $13.5M from $7.9M.","Net loss $13.2M vs $7.0M YoY; cash and investments $256.3M at June 30, 2026.","FY2026 revenue guidance raised to $116-120M, ~59% growth at midpoint vs 2025.","Launched eMTBR-tau blood assay and NULISAseq Immune 340 Panel; expanded Alzheimer's partnership with Gates Ventures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342378","json":"https://secwatch.observer/filing/0001193125-26-342378.json","markdown":"https://secwatch.observer/filing/0001193125-26-342378.md","text":"https://secwatch.observer/filing/0001193125-26-342378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/0001193125-26-342378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/ck0002104204-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:11:28.167574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}